Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H28N4O3.CH4O3S |
Molecular Weight | 564.653 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CN(C)C[C@@H]1CCN2C=C(C3=C2C=CC=C3)C4=C(C(=O)NC4=O)C5=CN(CCO1)C6=C5C=CC=C6
InChI
InChIKey=DUHQBKLTAVUXFF-FERBBOLQSA-N
InChI=1S/C28H28N4O3.CH4O3S/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24;1-5(2,3)4/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34);1H3,(H,2,3,4)/t18-;/m0./s1
Molecular Formula | C28H28N4O3 |
Molecular Weight | 468.5469 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | CH4O3S |
Molecular Weight | 96.106 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500068826.pdfCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23404115 | https://www.ncbi.nlm.nih.gov/pubmed/19825373 | https://www.ncbi.nlm.nih.gov/pubmed/15380221
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500068826.pdf
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23404115 | https://www.ncbi.nlm.nih.gov/pubmed/19825373 | https://www.ncbi.nlm.nih.gov/pubmed/15380221
Ruboxistaurin is an orally bioavailable, selective, potent inhibitor of protein kinase C β developed for treating diabetic retinopathy. In vitro and in vivo non-clinical models have demonstrated that Ruboxistaurin decreases PKC β activity and ameliorates many of the effects of PKC β on pathologic processes in the retina. Ruboxistaurin prevents the slowing of retinal blood flow that is observed by fluorescein video angiography in the eyes of diabetic rats. It is also reported to cause regression of retinal neovascularization produced by laser-induced major branch vein occlusions in a porcine model. Ruboxistaurin positively affected the diabetes-induced retinal blood flow abnormalities in a Phase Ib study in diabetic patients. Ruboxistaurin is in phase III clinical trials for the treatment of diabetic nephropathy and diabetic macular edema. Eli Lilly had submitted Ruboxistaurin for approval in the US and the EU; however, the company subsequently discontinued development as it was unable to demonstrate sufficient efficacy
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3045 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15380221 |
5.9 nM [IC50] | ||
Target ID: CHEMBL299 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12954055 |
360.0 nM [IC50] | ||
Target ID: CHEMBL2938 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12954055 |
300.0 nM [IC50] | ||
Target ID: CHEMBL3616 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12749884 |
52.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23404115
32 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19825373
HUVECs co-cultured with fibroblasts were cultivated in the presence or absence of various concentrations of ruboxistaurin (0.1 and 1 mkM) plus VEGF (10 ng/ml) at days 1, 4, 7 and 9. The ruboxistaurin was dissolved in dimethyl sulfoxide (DMSO, final concentration of DMSO was 0.1%). DMSO (0.1%) was added to the non-drug control (control group). At day 11, cells were fixed in 70% ethanol. The cells were incubated with diluted primary antibody (mouse anti-human CD31, 1 : 4000) for 1 h at 37 C, and with the secondary antibody (goat anti-mouse IgG alkaline phosphataseconjugated antibody, 1 : 500) for 1 h at 37 C. Visualization was achieved using 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:47:21 GMT 2023
by
admin
on
Fri Dec 15 15:47:21 GMT 2023
|
Record UNII |
6V860VW8AO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000089588
Created by
admin on Fri Dec 15 15:47:21 GMT 2023 , Edited by admin on Fri Dec 15 15:47:21 GMT 2023
|
PRIMARY | |||
|
192050-59-2
Created by
admin on Fri Dec 15 15:47:21 GMT 2023 , Edited by admin on Fri Dec 15 15:47:21 GMT 2023
|
PRIMARY | |||
|
m9693
Created by
admin on Fri Dec 15 15:47:21 GMT 2023 , Edited by admin on Fri Dec 15 15:47:21 GMT 2023
|
PRIMARY | |||
|
6V860VW8AO
Created by
admin on Fri Dec 15 15:47:21 GMT 2023 , Edited by admin on Fri Dec 15 15:47:21 GMT 2023
|
PRIMARY | |||
|
11577725
Created by
admin on Fri Dec 15 15:47:21 GMT 2023 , Edited by admin on Fri Dec 15 15:47:21 GMT 2023
|
PRIMARY | |||
|
DBSALT002088
Created by
admin on Fri Dec 15 15:47:21 GMT 2023 , Edited by admin on Fri Dec 15 15:47:21 GMT 2023
|
PRIMARY | |||
|
DTXSID10172762
Created by
admin on Fri Dec 15 15:47:21 GMT 2023 , Edited by admin on Fri Dec 15 15:47:21 GMT 2023
|
PRIMARY | |||
|
SUB22089
Created by
admin on Fri Dec 15 15:47:21 GMT 2023 , Edited by admin on Fri Dec 15 15:47:21 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
PARENT -> SALT/SOLVATE |